What should you pay attention to when using capmatinib?

Capmatinib (Capmatinib) is an oral targeted drug, mainly used to treat patients with non-small cell lung cancer (NSCLC) who have developed MET gene mutations, especially It is targeted at patients who have skipping mutations in exon 14 of MET (METex14) and who have failed other treatments. Although capmatinib has demonstrated good efficacy in many clinical trials, patients still need to pay attention to some important matters during use to ensure the effectiveness and safety of the drug. Here are a few key points to pay attention to when using capmatinib.

1. Genetic testing is crucial

The therapeutic effect of capmatinib is directly related to the MET gene mutation status, so genetic testing is crucial before use. Only patients with positive METexon14 skipping mutations (METex14) are suitable for capmatinib. Genetic testing not only helps determine indications for treatment, but can also rule out other genetic mutations or different types of lung cancer, which is important to ensure the efficacy of drugs and reduce unnecessary side effects. Therefore, patients should ensure that they undergo comprehensive genetic testing before using capmatinib, and have a professional physician determine whether it is suitable for use based on the results.

2. Liver function monitoring

Capmatinib may exert a certain burden on the liver during treatment, so liver function needs to be monitored regularly during use. Studies have found that capmatinib may cause mild to moderate elevations in liver enzymes, and some patients may experience liver damage. To ensure safety, patients should regularly check liver function indicators, such as ALT, AST and bilirubin levels during treatment. If liver function abnormalities are significant, the patient should report to the doctor promptly, and the drug dose may need to be adjusted or treatment suspended. For patients with liver function problems, doctors may decide whether to adjust the treatment plan or conduct closer monitoring based on their condition.

3. Drug Interactions

There may be interactions between capmatinib and other drugs, especially drugs that affect liver enzymes. For example, capmatinib is metabolized by the enzyme CYP3A4 and therefore, potent CYP3A4Inhibitors (such as certain antifungals, antiviral drugs) may increase the plasma concentration of capmatinib, leading to an increase in side effects. Conversely, strong CYP3A4 inducers (such as certain antiepileptic drugs) may reduce the efficacy of capmatinib. Patients should inform their doctor about all medications they are taking while taking capmatinib, including prescription drugs, over-the-counter drugs, herbal remedies, and supplements, to avoid adverse drug interactions.

4. Side Effect Management

Side effects of capmatinib are generally common but are tolerated by most patients. Common side effects include gastrointestinal discomfort (such as nausea, vomiting, diarrhea), fatigue, loss of appetite, and rash. Although these side effects are usually mild, they may affect the patient's daily life. In order to alleviate these uncomfortable symptoms, patients can take some measures, such as taking medicine after meals, replenishing water, and rationally adjusting their diet. In the event of more serious side effects, patients should contact their doctor promptly and adjust the drug dosage or suspend use if necessary.

Among them, the one that needs the most attention is lung problems. A small number of patients may experience respiratory side effects such as pneumonia and interstitial lung disease, manifesting as symptoms such as cough, dyspnea, or fever. If similar symptoms occur, discontinue medication immediately and seek medical help. In addition, capmatinib may also cause edema, especially in the early stages of treatment, which may manifest as edema of the lower extremities. Patients should check their weight regularly and communicate with their doctor if they develop significant symptoms of edema.

5. Use during pregnancy and lactation

Capmatinib is classified as a pregnancy C drug, which means it has certain toxic effects on the fetus in animal tests, but there is not enough human clinical data yet. Therefore, the use of capmatinib should be avoided during pregnancy. If pregnancy is planned, patients should fully communicate with their doctor before using capmatinib and use effective contraceptive measures. It is unknown whether capmatinib is excreted in breast milk, so breastfeeding women should also avoid using the drug or stop breastfeeding during treatment.

6. Long-term treatment and drug resistance issues

The treatment of capmatinib for non-small cell lung cancer is usually long-term, and patients may need to continue taking it for several months or even years according to their doctor's recommendations. However, drug resistance is also a problem that cannot be ignored. Some patients may develop drug resistance during treatment, manifesting as disease progression or tumor recurrence. Doctors usually adjust treatment strategies according to changes in the condition, and may recommend combining other drugs or switching to other targeted treatment options. Therefore, patients should maintain close contact with their doctors and undergo regular examinations and evaluations.

In short, capmatinib, as a targeted drug, has significant efficacy, but there are also some potential side effects and precautions. When using capmatinib, patients need to pay close attention to genetic testing, liver function monitoring, drug interactions, side effects management, etc., and maintain good communication with their doctors to ensure the efficacy and safety of the drug. At the same time, patients should maintain long-term treatment compliance and deal with any problems during treatment in a timely manner.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib